Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Lymphoma, T-Cell, Peripheral 6Hematologic Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Parathyroid Neoplasms 2Otorhinolaryngologic Neoplasms 2Osteosarcoma 2Neoplasms 2Multiple Myeloma 2Mixed Tumor, Mesodermal 2Mesothelioma, Cystic 2Mesothelioma 2Lymphoma, T-Cell 2Lymphoma 2Liposarcoma 2Leiomyosarcoma 2Kidney Neoplasms 2Hemangiosarcoma 2Head and Neck Neoplasms 2Fibrosarcoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Chondrosarcoma 2Carcinoma, Small Cell 2Breast Neoplasms 2Adenosarcoma 2

Interventions

Dexamethasone 307Bortezomib 161Lenalidomide 130pomalidomide 112daratumumab 94carfilzomib 69Calcium Dobesilate 41Cyclophosphamide 40belantamab mafodotin 31elotuzumab 30fludarabine 27ixazomib 23isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Myeloma × belinostat × Clear all
NCT00131261 2015-07-08

Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

Valerio Therapeutics

Phase 2 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

NCT00431340 2015-07-08

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Valerio Therapeutics

Phase 2 Terminated
4 enrolled
Plasma cell

Multiple Myeloma, Bone Marrow Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡